Polymorphisms in DNA-Repair Genes in a Cohort of Prostate Cancer Patients from Different Areas in Spain: Heterogeneity between Populations as a Confounding Factor in Association Studies by Henríquez-Hernández, Luis Alberto et al.
Polymorphisms in DNA-Repair Genes in a Cohort of
Prostate Cancer Patients from Different Areas in Spain:
Heterogeneity between Populations as a Confounding
Factor in Association Studies
Luis Alberto Henrı́quez-Hernández1,2,3*, Almudena Valenciano2, Palmira Foro-Arnalot4, Marı́a
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Adriana Ayala-Gil9, Pablo Fernández-Gonzalo9, Montse Ferrer10, Ferrán Guedea11,
Gemma Sancho-Pardo12, Jordi Craven-Bartle12, Marı́a José Ortiz-Gordillo13, Patricia Cabrera-Roldán13,
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Radiation Oncology, Institut Català d’Oncologia ICO, L’Hospitalet de Llobregat, Barcelona, Spain, 12 Radiation Oncology Department, Hospital de la Santa Creu i Sant Pau,
Barcelona, Spain, 13 Radiation Oncology Department, Hospital Universitario Virgen del Rocı́o, Sevilla, Spain, 14 Immonology Department, Hospital Universitario de Gran
Canaria Dr. Negrı́n, Las Palmas, Spain
Abstract
Background: Differences in the distribution of genotypes between individuals of the same ethnicity are an important
confounder factor commonly undervalued in typical association studies conducted in radiogenomics.
Objective: To evaluate the genotypic distribution of SNPs in a wide set of Spanish prostate cancer patients for determine
the homogeneity of the population and to disclose potential bias.
Design, Setting, and Participants: A total of 601 prostate cancer patients from Andalusia, Basque Country, Canary and
Catalonia were genotyped for 10 SNPs located in 6 different genes associated to DNA repair: XRCC1 (rs25487, rs25489,
rs1799782), ERCC2 (rs13181), ERCC1 (rs11615), LIG4 (rs1805388, rs1805386), ATM (rs17503908, rs1800057) and P53
(rs1042522). The SNP genotyping was made in a Biotrove OpenArrayH NT Cycler.
Outcome Measurements and Statistical Analysis: Comparisons of genotypic and allelic frequencies among populations, as
well as haplotype analyses were determined using the web-based environment SNPator. Principal component analysis was
made using the SnpMatrix and XSnpMatrix classes and methods implemented as an R package. Non-supervised hierarchical
cluster of SNP was made using MultiExperiment Viewer.
Results and Limitations: We observed that genotype distribution of 4 out 10 SNPs was statistically different among the
studied populations, showing the greatest differences between Andalusia and Catalonia. These observations were
confirmed in cluster analysis, principal component analysis and in the differential distribution of haplotypes among the
populations. Because tumor characteristics have not been taken into account, it is possible that some polymorphisms may
influence tumor characteristics in the same way that it may pose a risk factor for other disease characteristics.
Conclusion: Differences in distribution of genotypes within different populations of the same ethnicity could be an
important confounding factor responsible for the lack of validation of SNPs associated with radiation-induced toxicity,
especially when extensive meta-analysis with subjects from different countries are carried out.
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Introduction
Genetic polymorphisms are variants of the genome that appear
by mutations in some individuals, are transmitted to offspring and
acquire some frequency (at least 1%) in the population after many
generations. Polymorphisms are the basis of evolution and those
that are consolidated may be silent or provide benefits to
individuals, but can also be involved in disease development [1].
The most frequent polymorphisms are single nucleotide polymor-
phisms (SNPs). The ethnic origin of a population determines the
distribution of genotypes in a population, and has not to be equal
to others. Moreover, differences observed within populations of
the same ethnic origin suggest that race is not a sufficient factor to
ensure the homogeneity of the sample. In that sense, it is known
the presence of several significant axes of stratification, most
prominently in a northern-south-eastern trend, but also along an
east-west axis, among the genotype distribution of European
population [2]. In the case of Spain, although populations
inhabiting the Iberian Peninsula show a substantial genetic
homogeneity [3], there are findings suggesting that Northwest
African influences existing among the Spanish populations and
these differences might increase the risk for false positives in
genetic epidemiology studies [4].
Radiation therapy (RT) is an effective treatment offered to
patients with localized prostate cancer as a viable alternative to
surgery [5]. Although both therapies showed comparable results in
terms of survival [6], the main differences between them are
related to adverse effects. Tumour control by RT requires the use
of maximum dose that can be delivered while maintaining a
tolerance risk of normal tissue toxicity, being clinical toxicity the
factor limiting the efficacy of the treatment [7]. The role of
genetics in the response of normal tissues to RT is widely accepted
by the scientific community, and it would help to explain why
patients treated with RT experience a large variation in normal
tissue toxicity, even when similar doses and schedules are
administered [8]. Radiation causes the loss of structure and
function of most biologic molecules, including DNA. The
individual DNA repair capacity consists of several mechanisms
(nucleotide and base excision repair, homologous recombination,
non-homologous endjoining, mismatch repair and telomere
metabolism) and the individual capacity to repair damaged
DNA may modify the response of tumour tissue and normal
tissue to radiation [9]. Thus, studies of candidate genes have been
focused on genes mainly involved in DNA damage recognition
and repair (eg, ATM, XRCC1, XPD, ERCC1, LIG4, and TP53
among others), and also in free radical scavenging (eg, SOD2), or
anti-inflammatory response (eg, TGFB1).
The association between SNPs and radiation toxicity has been
deeply explored [10] and numerous consortia have been formed to
identify common genetic variations associated with the develop-
ment of radiation toxicity [11]. Although promising, the overall
results failed at the validation stage [12] and today, the
development of a SNP signature associated to the prediction of
toxicity is still far away. Although this lack of association could be
explained by different reasons (presence of confounding factors,
insufficient sample size, and lack of consensus in the methodology
used in terms of genotyping, statistics, and even in the grading of
radiation toxicity) [13], the heterogeneity of the studied popula-
tions is a factor whose effect has been commonly underestimated.
With all those assumptions in mind, we designed a study aimed
to evaluate the genotypic distribution of 10 SNPs in 6 different
genes involved in DNA repair and classically associated to
radiation-induced toxicity, in a wide set of Spanish prostate
cancer patients, to determine the homogeneity of the population
and to disclose potential undervalued confounders in the
association between SNPs and radiation toxicity.
Materials and Methods
1. Patients
A total of 601 patients with non-metastatic localized prostate
cancer (PCa) were included in the study. Geographical distribution
of patients was as follows (Table 1): 91 (15.14%) from Andalusia,
51 (8.48%) from Basque Country, 238 (39.60%) from Canary and
221 (36.77%) from Catalonia. All patients were from Spanish
origin and all of them received written informed consent before
sample collection. All participants provided their written informed
consent to participate in this study. The study was approved by the
Research and Ethics Committee of each institution participant in
the study: Hospital Universitario de Gran Canaria Dr. Negrı́n (Las
Palmas de Gran Canaria), Hospital de la Esperanza. Parc de Salut
Mar (Barcelona), Hospital Universitario Virgen de las Nieves
(Granada), Hospital Universitari de Bellvite (L’Hospitalet de
Llobregat), Onkologikoa (Guipuzcoa), Institut Català d’Oncologia
(L’Hospitalet de Llobregat), Hospital de la Santa Creu i Sant Pau
(Barcelona) and Hospital Universitario Virgen del Rocı́o (Sevilla).
2. DNA Isolation and Quantification
All the blood samples were sent to the Hospital Universitario de
Gran Canaria Dr. Negrı́n for DNA extraction and subsequent
analyses. DNA was isolated from 300 ml of whole-blood in an
iPrep purification system (Applied Biosystems, Foster City, CA)
using the iPrepTM PureLinkTM gDNA Blood Kit (Applied
Biosystems). DNA was quantified and the quality of samples was
determined in a NanoDrop 2000 (Thermo Scientific, Wilmington,
DE).
Table 1. Regional ancestry of study participants.
Regional ancestry n (%) No. of hospitals
Andalusia 91 (15.14) 2
Basque Country 51 (8.48) 1
Canary 238 (36.60) 1
Catalonia 221 (36.77) 4
Total 601 (100) 8
doi:10.1371/journal.pone.0069735.t001
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Table 2. Description of SNPs included in the study and analyzed by OpenArray.
Gene name Symbol Assay ID SNP ID Alleles Chr Position
X-ray repair complementing defective repair in Chinese hamster cells 1
XRCC1 C____622564_10 rs25487 C/T 19q13 44055726
XRCC1 C____622570_10 rs25489 C/T 19q13 44056412
XRCC1 C__11463404_10 rs1799782 A/G 19q13 44057574
Excision repair cross-complementing rodent repair deficiency, complementation group 2
ERCC2/XPD C___3145033_10 rs13181 G/T 19q13 45854919
Excision repair cross-complementing rodent repair deficiency, complementation group 1
ERCC1 C___2532959_1_ rs11615 A/G 19q13 45923653
Ligase IV
LIG4 C__11427969_20 rs1805388 A/G 13q33 108863591
LIG4 C__11427968_10 rs1805386 A/G 13q33 108861913
Ataxia telangiectasia mutated
ATM C__33307908_10 rs17503908 G/T 11q22 108215397
ATM C__45273750_10 rs1800057 C/G 11q22 108143456
Tumour protein P53
P53 C___2403545_10 rs1042522 C/G 17p13 7579472
Abbreviations: Chr, chromosome; C, cytosine; T, thymine; A, adenine; G, guanine. All the assays were commercially available at Applied Biosystems (see Assay ID).
doi:10.1371/journal.pone.0069735.t002
Figure 1. Scatter plots showing genotyping of SNP rs1042522 in (A) Andalusia, (B) Basque Country, (C) Canary, and (D) Catalonia
using a Biotrove OpenArrayH NT Cycler. Each graph depicts a scattered plot of one allele (FAM probe) versus the other allele (VIC probe). Those
samples that are homozygous appear in blue or red; heterozygous samples contain fluorescence from both probes and appear in green. The NTCs
appear in light-blue squares and represent the background fluorescence from samples with no template DNA. Samples non-determined appear as
black points and samples not amplified appear as orange points. The scatter plots were obtained from the TaqMan Genotyper software version 1.0.1.
doi:10.1371/journal.pone.0069735.g001
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3. Genes and SNPs
A total of 10 SNPs in 6 different key genes involved in DNA
repair were studied: X-ray repair cross-complementing protein 1
(XRCC1) [14,15], excision repair cross-complementing rodent
repair deficiency, complementation group 2 (ERCC2) [16],
excision repair cross-complementing rodent repair deficiency,
complementation group 1 (ERCC1) [17], ligase IV (LIG4) [18],
ataxia telangiectasia mutated (ATM) [19], and tumour protein p53
(TP53) [20]. Because RT acts producing DNA damage and
genetic variation in DNA repair and damage response modify the
susceptibility to radiotherapy, these SNPs have been classically
associated to radiation-induced toxicity in several tumor types.
Description of SNPs is contained in Table 2.
4. Genotyping
The SNP genotyping was made in a Biotrove OpenArrayH NT
Cycler (Applied Biosystems). DNA for OpenArray (OA) was
diluted at a concentration of 50 ng/ml and a ratio of A260/A280
and A260/230 of 1.7–1.9. A total of 300 ng of genomic DNA was
used. A final amount of 150 ng was incorporated into the array
with the autoloader and genotyped according to the manufactur-
er’s recommendations. A non-template control (NTC) consisting
of DNase-free double-distilled water was introduced within each
assay. When the DNA and master mix were transferred, the
loaded OA plate was filled with an immersion fluid and sealed
with glue. The multiplex TaqMan assay reactions were carried out
in a Dual Flat Block (384-well) GeneAmp PCR System 9700
(Applied Biosystems) with the following PCR cycle: an initial step
at 93uC for 10 minutes followed by 50 cycles of 45 seconds at
95uC, 13 seconds at 94uC and 2 minutes, 14 seconds at 53uC;
followed by a final step during 2 minutes at 25uC and holding at
4uC.
The fluorescence results were read using the OpenArrayH SNP
Genotyping Analysis software version 1.0.5. (Applied Biosystems).
The genotyping analysis was made with the TaqMan Genotyper
software version 1.0.1. (available at: ttp://www.invitrogen.com/
Figure 2. Non-supervised hierarchical clustering of SNPs in prostate cancer patients from (A) Andalusia, (B) Basque Country, (C)
Canary and (D) Catalonia. Clustering was made using Euclidean distance correlation and average linkage, and was processed and displayed with
MultiExperiment Viewer (http://www.tigr.org). The dendogram shows clustering of SNPs. The gene symbol was added to identify each SNP. Lines
below each panel shows the two main clusters generated.
doi:10.1371/journal.pone.0069735.g002
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site/us/en/home/Global/forms/taqman-genotyper-software-
download-reg.html) using autocalling as the call method. The
quality value of the data points genotype was determined by a
threshold above 0.95. Genotyping analysis was done for each
population separately (Figure 1).
5. Statistical Analysis
Genotype and allelic frequencies were determined using the
web-based environment SNPator (SNP Analysis To Results, from
the Spain’s National Genotyping Center and the National Institute
for Bioinformatics) [21]. Relative excess heterozygosity was
determined to check compatibility of genotype frequencies with
Hardy-Weinberg equilibrium (HWE). Thus, p-values from the
standard exact HWE lack of fit test were calculated using SNPator.
Comparisons of genotypic and allelic frequencies among popula-
tions, as well as haplotype analyses were also done in SNPator.
Principal component analysis (PCA) was made using the
SnpMatrix and XSnpMatrix classes and methods [22], imple-
mented as an R package and available from Bioconductor (as of
version 2.11; http://bioconductor.org). It consists in the transfor-
mation of the set of original variables in another set of variables –
principal components – obtained as a linear combination of those.
The new variables retain all the information, but most of the
principal components have so small variability that can be
ignored. Thus, few components (generally 3 or less) can represent
and explain reasonably the set of objects of the sample without loss
of information. PCA reduces the complexity of the data and
permits the graphical representation of the variables.
Non-supervised hierarchical clustering [23] of SNP in each
population was made using MultiExperiment Viewer (available at:
www.tigr.org). Clustering was made using Euclidean distance
correlation and average linkage. To success perform the clusters,
Table 3. Genotype and allelic frequencies of gene
polymorphisms in this study.
Call rate Genotypes HWE Alleles
XRCC1
rs25487 CC CT TT C T
Andalusia 0.79 0.49 0.34 0.18 ns 0.65 0.35
Basque Country 0.80 0.44 0.51 0.05 ns 0.70 0.30
Canary 0.95 0.48 0.41 0.11 ns 0.68 0.32
Catalonia 0.83 0.36 0.55 0.09 * 0.63 0.37
P value 0.012
rs25489 CC CT TT C T
Andalusia 0.91 0.81 0.19 0.00 ns 0.90 0.10
Basque Country 1.00 0.86 0.14 0.00 ns 0.93 0.07
Canary 0.97 0.87 0.13 0.00 ns 0.93 0.07
Catalonia 0.98 0.90 0.09 0.01 ns 0.95 0.05
P value 0.178
rs1799782 AA AG GG A G
Andalusia 0.85 0.00 0.09 0.91 ns 0.05 0.95
Basque Country 1.00 0.00 0.08 0.92 ns 0.04 0.96
Canary 0.99 0.01 0.12 0.87 ns 0.07 0.93
Catalonia 0.98 0.01 0.11 0.88 ns 0.06 0.94
P value 0.936
ERCC2
rs13181 GG GT TT G T
Andalusia 0.74 0.19 0.15 0.66 * 0.27 0.73
Basque Country 1.00 0.06 0.37 0.57 ns 0.25 0.75
Canary 0.98 0.11 0.45 0.44 ns 0.33 0.67
Catalonia 0.97 0.09 0.53 0.38 ns 0.35 0.65
P value 0.0001
ERCC1
rs11615 AA AG GG A G
Andalusia 0.70 0.58 0.20 0.22 * 0.68 0.32
Basque Country 1.00 0.43 0.43 0.14 ns 0.65 0.35
Canary 0.98 0.43 0.41 0.16 ns 0.63 0.37
Catalonia 0.99 0.32 0.52 0.16 ns 0.58 0.42
P value 0.001
LIG4
rs1805388 AA AG GG A G
Andalusia 0.74 0.06 0.12 0.82 ns 0.12 0.88
Basque Country 0.98 0.04 0.38 0.58 ns 0.23 0.77
Canary 0.99 0.03 0.25 0.72 ns 0.15 0.85
Catalonia 0.99 0.05 0.22 0.73 ns 0.16 0.84
P value 0.051
rs1805386 AA AG GG A G
Andalusia 0.85 0.78 0.16 0.06 ns 0.85 0.15
Basque Country 0.98 0.84 0.16 0.00 ns 0.92 0.08
Canary 0.96 0.73 0.25 0.02 ns 0.85 0.15
Catalonia 0.98 0.66 0.28 0.06 ns 0.80 0.20
P value 0.029
ATM
rs17503908 GG GT TT G T
Table 3. Cont.
Call rate Genotypes HWE Alleles
Andalusia 0.81 0.03 0.08 0.89 ns 0.07 0.93
Basque Country 0.98 0.00 0.20 0.80 ns 0.10 0.90
Canary 0.99 0.01 0.20 0.79 ns 0.10 0.90
Catalonia 0.98 0.01 0.17 0.82 ns 0.09 0.91
P value 0.088
rs1800057 CC CG GG C G
Andalusia 0.80 1.00 0.00 0.00 * 1.00 0.00
Basque Country 1.00 0.94 0.06 0.00 ns 0.97 0.03
Canary 0.97 0.95 0.04 0.01 ns 0.97 0.03
Catalonia 0.99 0.92 0.08 0.00 ns 0.96 0.04
P value 0.186
TP53
rs1042522 CC CG GG C G
Andalusia 0.68 0.63 0.26 0.11 ns 0.76 0.24
Basque Country 1.00 0.41 0.49 0.10 ns 0.66 0.34
Canary 0.97 0.61 0.32 0.07 ns 0.77 0.23
Catalonia 0.98 0.60 0.35 0.05 ns 0.78 0.22
P value 0.059
Statistical differences among genotypes andHardy-Weinberg equilibrium (HWE)
are shown. Abbreviations: ns, non-significant. Differences in the genotype
distribution were assessed by x2 test. Populations showing no HWE were
indicated with an asterisk (P,0.01).
doi:10.1371/journal.pone.0069735.t003
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wild homozygous was encoded as 21, heterozygous as 0 and
mutated homozygous as 1.
All additional statistical analyses were performed using PASW
Statistics 15 (IBM Corporation, Armonk, NY, USA).
Results
All the genotyped samples met quality criteria as stated above,
and all samples were genotyped with the same batch of material at
Figure 3. Plot of the top two principal components from the analysis of populations (A), and boxplot of component 1 among the
different populations (B). Symbols in plot A: u (black), Andalusia; D (red), Basque Country;+(green), Canary; 6 (blue), Catalonia. Abbreviations in
plot B: And, Andalusia; Basq, Basque Country; Can, Canary; Cat, Catalonia.
doi:10.1371/journal.pone.0069735.g003
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the same time. A total of 601 PCa patients were genotyped for
10 SNPs. Of the 6,010 possible determinations, 94.36% were
successfully genotyped. The call rates among populations were
(median (range)): 79.5% (68.1–91.2%) for Andalusia, 100% (80.4–
100%) for Basque Country, 97.7% (94.5–99.2%) for Canary, and
97.9% (83.3–99.1%) for Catalonia.
The genotypic and allelic frequencies are shown in Table 3. A
relative excess of heterozygosity, indicating a deviation from
HWE, was observed in 4 SNPs from 2 different populations:
rs25487 (XRCC1) in subjects from Catalonia and rs13181
(ERCC2), rs11615 (ERCC1) and rs180057 (ATM) in subjects
from Andalusia (Table 3). The genotype distribution was different
between the study populations in 4 of the 10 SNPs: rs25487,
rs13181, rs11615, and rs1805386 (LIG4) (x2 test, Table 3),
showing a differential distribution of genotypes among popula-
tions. A non-supervised hierarchical cluster was performed trying
to visualize the differences in the genotype distributions among the
four populations. Thus, as shown in Figure 2, polymorphisms were
distributed into two main clusters, each one with different number
and identity of SNPs, suggesting heterogeneity among populations.
Moreover, the web-based tool SNPator was used to compare
populations individually one against one. Differences in genotypic
distributions were mainly present between Andalusia and the other
populations (x2 test, Table 4). According to that result, the
populations from Catalonia and Andalusia showed the greatest
differences, with 3 SNPs (rs25487, rs13181 and rs11615) differen-
tially distributed among the PCa patients from both populations.
Principal component analysis (PCA) was done trying to identify
global differences among populations. Components 1 and 2 were
responsible for the 15.3% and 14.3% of the variance, respectively.
When both components were plotted, the main components
seemed not to discriminate between populations (Figure 3A).
However, when components were analyzed separately, the first
one could distinguish between the populations of Andalusia and
Catalonia (Figure 3B), corroborating the results observed in
Table 4 and clearly showing the differences in the distribution of
genotypes between the analyzed populations.
Finally, haplotype analysis was performed in SNPator. As
shown in Table 5, the three most frequent haplotypes were
different among populations. Thus, for SNPs in chromosome 11
(those located in ATM gene), the haplotype GG was absent in the
Andalusian population. For SNPs in chromosome 13 (those
located in LIG4 gene), haplotypes GG and AA showed a different
distribution among the populations. In the case of SNPs in
chromosome 19 (those located in XRCC1, ERCC2 and ERCC1
genes), haplotype CCGGG was present only in PCa patients from
Canary and Catalonia, while haplotype CCGTG was present only
in PCa patients from Andalusia and Basque Country. The fact
that the most frequent haplotypes were equal in all populations
suggests a similarity between individuals of the same ethnicity.
Discussion
Radiogenomics is the study of genetic variants, primarily single
nucleotide polymorphisms (SNPs), associated with the develop-
ment of radiotherapy toxicity, in an attempt to find an assay
capable of predicting which cancer patients are most likely to
develop adverse effects after RT [9]. The prediction of normal
tissue toxicity would allow the adjusting of radiation doses
individually for each patient, especially when higher radiation
Table 4. Comparison among populations of allelic and
genotypic frequencies.
Comparison Allelic frequencies Genotypic frequencies
Can vs. And – rs13181
Can vs. Basq – –
Can vs. Cat – –
And vs. Basq – rs1805388
rs13181
And vs. Cat – rs25487
rs13181
rs11615
Basq vs. Cat rs1805386 –
SNPs differentially distributed are shown.
Abbreviations: Can, Canary; And, Andalusia; Basq, Basque Country; Cat,
Catalonia. The analyses of the genotypic frequencies were performed including
the three possible genotypes. Differences were significant with p values ,0.01.
doi:10.1371/journal.pone.0069735.t004
Table 5. Analysis of the three most frequent haplotypes (%) in chromosomes 11 (ATM gene), 13 (Lig4 gene) and 19 (XRCC1, ERCC2
and ERCC1 genes) among the studied populations.
Haplotype/chr11 Andalusia fr Basque Country fr Canary fr Catalonia fr
Hap 1 CT 93.18 CT 89.82 CT 89.15 CT 91.27
Hap 2 CG 6.80 CG 7.24 CG 8.23 CG 4.87
Hap 3 GT 0.02 GG 2.74 GG 2.39 GG 3.86
Haplotype/chr13
Hap 1 AG 76.08 AG 69.81 AG 70.17 AG 64.14
Hap 2 GG 11.89 AA 22.27 AA 15.22 GG 19.60
Hap 3 AA 10.53 GG 7.11 GG 14.49 AA 16.23
Haplotype/chr19
Hap 1 CCGTA 32.52 CCGTA 31.19 CCGTA 27.37 CCGTA 26.11
Hap 2 TCGTA 14.86 CCGTG 14.81 TCGTA 17.03 TCGTA 14.31
Hap 3 CCGTG 11.37 TCGTA 14.29 CCGGG 12.32 CCGGG 12.37
Abbreviations: chr, chromosome; fr, frequency; Hap, haplotype. Haplotypes in chr11 is shaped with locus rs1800057 and 17503908, respectively; haplotypes in chr13 is
shaped with locus rs1805386 and 1805388, respectively; haplotypes in chr19 is shaped with locus rs25487, rs25489, rs1799782, rs13181, and rs11615, respectively.
doi:10.1371/journal.pone.0069735.t005
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dose levels are associated with improved biochemical control
outcomes and reduction in distant metastases in PCa patients [24].
The role of genetics in radiation-toxicity has been proved [25]. In
that sense, genetics seem to contribute to explain the high inter-
individual variability observed between cases, even when patients
are similar and are treated with the same treatment schedule [26].
However, although it has been published a lot of bibliography
reporting the predictive role of some SNPs in normal tissue
toxicity, the validation studies have failed, calling into question the
utility of SNPs as a tool for predicting radiation-induced toxicity
[12].
Population association between genotype at a particular locus
and a binary trait (such as presence/absence of radiation-induced
toxicity) can arise in three ways [27]: i) the locus may be causally
related to the disease (different alleles carrying different risks), ii)
the locus may not itself be casual (but may be sufficiently close to a
causal locus as to be in linkage disequilibrium whit it), or iii) the
association may be due to confounding by population stratification
or admixture. Confounding may act to create population
association in the absence of a casual link or obscure a casual
relationship. Thus, it is important to exclude spurious association
by appropriate design and/or analysis of studies, taken into
account that biases that result from systematic error (such as
selection biases or biases in measuring outcomes) persist as the
sample size increases. Confounding would arise if the population
contained several ethnic groups, if allele frequencies at the locus of
interest differed between groups, and if disease frequency also
differed between groups for reasons quite unrelated to the locus of
interest. It is known that ethnicity influences the applicability of
pharmacogenetics [28].
Canary population, as well as the rest of populations included in
this study, is considered as Caucasian. However, the natural
history of, for example, Canary and Basque Country, are different.
Thus, while Canary population has influence from Northwest
Africa migration and European colonisation [29], Basques have a
different origin [30]. However, in a recent published paper, 30
individuals from 10 different populations from Spain (Canary
population was not included in that study) were genotyped for
120 SNPs, concluded that the studied populations were genotyp-
ically similar [3]. None of the SNPs considered in the present study
were included in this previous article. We found that genotype
distribution of 4 SNPs was different among populations from
Andalusia, Basque Country, Canary and Catalonia. We compared
our findings with the largest cohort of PCa patients analyzed in
Spain [31]. A total of 698 Galician PCa patients were screened for
14 SNPs located in the ATM, ERCC2, LIG4, MLH1 and
XRCC3 genes. Three of these SNPs were included in our
multicenter study: rs1805388 (LIG4), rs1805386 (LIG4) and
rs1800057 (ATM). Genotypic distributions of rs1805388 and
rs1805386 were significantly different among Galician and the
populations included in the present study (x2 test, p = 0.001 and
p = 0.007, respectively), highlighting the variability between
populations of the same ethnicity (Caucasians) from the same
country in depending of each SNP. According to our results,
Andalusia was the population differentially distributed, showing
the greatest disparity with Catalan (results observed in x2 analyses
and PCA). Differences among populations were also evident in
haplotype analysis and subsequent distribution. Those results
suggest that each SNP need to be considered individually, trying to
find possible confounding variables that would be crucial for the
interpretation of results. In case-control studies, which is the usual
type of design in studies for discovering associations between SNPs
and radiation toxicity, the fundamental assumption is that these
two series of subjects (controls and cases) may be used to provide
unbiased estimates of the corresponding distributions among
affected and unaffected members of some underlying population
[27]. This fundamental assumption may not be met in practice,
leading to biased findings that fall into two broad classes: selection
bias caused by inappropriate sampling of cases and controls, and
information bias caused by differential measurement errors in
cases and controls. When the confounding variable is detected in
the study, the classical method in epidemiology is by stratification
of the analysis by the potentially confounding variable and testing
for association between factors of interest (i.e. genotype) and
disease within strata (i.e. grades of radiation-induced toxicity).
Concern over the presence of bias from population stratification in
genetic case-control studies should be alleviated by proper design
and analysis of case-control studies, evaluation of the likelihood of
major bias in a given study [32] and, if needed, methods for
correction [33].
The present study has some limitations that should be noted.
First, all subjects were PCa patients and the genotype frequency
may be different if it is compared with a population of healthy
subjects. However, in studies designed to evaluate possible
associations between SNPs and radiation toxicity, controls are
patients with null-low grade of toxicity and cases are patients with
high grade of toxicity, but all subjects are cancer patients. Thus,
this limitation could be considered as an advantage because it
mimics the standard design of such studies. Second, the number of
subjects from the different population varies widely. However, the
fact that the main differences were not found in the population
with the smallest number of patients (Basque Country, with
51 PCa) suggests that this limitation may not be decisive in the
interpretation of results. Moreover, if heterogeneity among
populations is considered a systematic bias, it is independent of
sample size. Third, to blind the analysis, no clinical data on
patients were available, that is, there are not data about TNM
staging, tumor grade, biochemical failure, or Gleason Score. In
that sense, it is possible that some polymorphism may influence
tumor characteristics in the same way that it may pose a risk factor
for other disease characteristics [34,35]. In the other hand, some
advantages should be highlighted: i) it includes a number of
subjects sufficient to have reliable data on the distribution of these
10 SNPs in the PCa populations studied (especially for Canary
and Catalonia); ii) all subjects were male, then avoiding the
possible bias generated by the gender; and iii) all the determina-
tions (6,010 in total) were performed with the same methodology
(OpenArray, Applied Biosystems), with the same batch of chips
and by the same investigator, thus minimizing biases from
technical origin.
Conclusions
Differences in distribution of genotypes within different
populations of the same ethnicity could be an important
confounding factor responsible for the lack of validation of those
SNPs associated with radiation-induced toxicity, especially when
extensive meta-analysis with subjects from different countries are
carried out [36]. Our results suggest that equality between people
(especially among those considered as control) should be checked
before proceeding with any further analysis.
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